{"id":171185,"date":"2026-06-15T13:07:42","date_gmt":"2026-06-15T13:07:42","guid":{"rendered":"https:\/\/www.m3globalresearch.com\/blog\/?p=171185"},"modified":"2026-06-15T13:57:13","modified_gmt":"2026-06-15T13:57:13","slug":"triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial","status":"publish","type":"post","link":"https:\/\/www.m3globalresearch.com\/blog\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\/","title":{"rendered":"Triple Receptor Agonist Retatrutide Achieves Significant Reductions in HbA1c and Body Weight in Phase III Trial"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n \t\t
\n\t\t\t\t\t\t\t\t\t

A Phase III randomised controlled trial published in The Lancet has found that retatrutide, a triple receptor agonist targeting GIP, GLP-1, and glucagon pathways simultaneously, produced substantial improvements in glycaemic control and body weight in adults with type 2 diabetes inadequately managed through diet and exercise alone.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t

The TRANSCEND-T2D-1 trial enrolled 537 adults across 48 sites in the United States, Mexico, and India. Participants received once-weekly subcutaneous injections of retatrutide at doses of 4 mg, 9 mg, or 12 mg, or placebo, over 40 weeks. The trial was designed to assess both glycaemic outcomes and weight reduction across dose levels.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t

Nearly 90% of participants receiving retatrutide achieved an HbA1c below 7.0%, with up to 40% reaching levels below 5.7%, within the normoglycaemic range. Fasting serum glucose levels also fell significantly across all active treatment groups. Participants lost an average of 11.5% to 15.3% of body weight depending on dose, compared with 2.6% in the placebo group. Those receiving the highest dose lost 15.3% on average, with weight loss still ongoing at the end of the 40-week period. Additional benefits included reductions in waist circumference, cholesterol levels, and blood pressure. Sixty-four per cent of participants in the highest dose group achieved the composite target of HbA1c below 6.5% and weight loss of at least 10%.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t

No cases of severe hypoglycaemia were reported. The most common adverse effects were gastrointestinal, including nausea, diarrhoea, and vomiting, and were generally mild to moderate in severity.<\/p>

The authors note that longer-term studies across broader patient populations are needed to evaluate the drug’s safety profile and suitability as a first-line therapy for early type 2 diabetes.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t

Source: Bajaj HS et al. Efficacy and safety of retatrutide in people with type 2 diabetes (TRANSCEND-T2D-1). The Lancet (2026). DOI: 10.1016\/s0140-6736(26)00967-0.<\/em><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\n<\/div>\n\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Retatrutide significantly improves hba1c and body weight outcomes, enhancing glycaemic control in adults with type 2 diabetes.<\/p>\n","protected":false},"author":11,"featured_media":171234,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_eb_attr":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[3200],"tags":[],"class_list":["post-171185","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-medical-news"],"acf":[],"yoast_head":"\nTriple Receptor Agonist Retatrutide Achieves Significant Reductions in HbA1c and Body Weight in Phase III Trial<\/title>\n<meta name=\"description\" content=\"Retatrutide significantly improves hba1c and body weight outcomes, enhancing glycaemic control in adults with type 2 diabetes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.m3globalresearch.com\/blog\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Triple Receptor Agonist Retatrutide Achieves Significant Reductions in HbA1c and Body Weight in Phase III Trial\" \/>\n<meta property=\"og:description\" content=\"Stage 2 chronic kidney disease often goes unnoticed, with estimated glomerular filtration rate levels still within the kidney function threshold.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.m3globalresearch.com\/blog\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"M3 Global Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/en-gb.facebook.com\/M3GlobalResearch\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-15T13:07:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-15T13:57:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.m3globalresearch.com\/blog\/wp-content\/uploads\/2026\/06\/HbA1c-and-Body-Weight-scaled.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Admin B.\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@M3GR_Community\" \/>\n<meta name=\"twitter:site\" content=\"@M3GR_Community\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Admin B.\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\\\/\"},\"author\":{\"name\":\"Admin B.\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#\\\/schema\\\/person\\\/2694d930280885a6f8adfd3c7090c10b\"},\"headline\":\"Triple Receptor Agonist Retatrutide Achieves Significant Reductions in HbA1c and Body Weight in Phase III Trial\",\"datePublished\":\"2026-06-15T13:07:42+00:00\",\"dateModified\":\"2026-06-15T13:57:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\\\/\"},\"wordCount\":296,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/HbA1c-and-Body-Weight-scaled.jpeg\",\"articleSection\":[\"Latest Medical News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\\\/#respond\"]}]},{\"@type\":[\"WebPage\",\"MedicalWebPage\"],\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\\\/\",\"url\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\\\/\",\"name\":\"Triple Receptor Agonist Retatrutide Achieves Significant Reductions in HbA1c and Body Weight in Phase III Trial\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/HbA1c-and-Body-Weight-scaled.jpeg\",\"datePublished\":\"2026-06-15T13:07:42+00:00\",\"dateModified\":\"2026-06-15T13:57:13+00:00\",\"description\":\"Retatrutide significantly improves hba1c and body weight outcomes, enhancing glycaemic control in adults with type 2 diabetes.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/HbA1c-and-Body-Weight-scaled.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/HbA1c-and-Body-Weight-scaled.jpeg\",\"width\":2560,\"height\":1707,\"caption\":\"Retatrutide significantly improves hba1c and body weight outcomes, enhancing glycaemic control in adults with type 2 diabetes.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Triple Receptor Agonist Retatrutide Achieves Significant Reductions in HbA1c and Body Weight in Phase III Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/\",\"name\":\"M3 Global Research\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#organization\",\"name\":\"M3 Global Research\",\"url\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":null,\"contentUrl\":null,\"width\":null,\"height\":null,\"caption\":\"M3 Global Research\"},\"image\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/en-gb.facebook.com\\\/M3GlobalResearch\\\/\",\"https:\\\/\\\/x.com\\\/M3GR_Community\",\"https:\\\/\\\/www.instagram.com\\\/m3globalresearch\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/10557915\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#\\\/schema\\\/person\\\/2694d930280885a6f8adfd3c7090c10b\",\"name\":\"Admin B.\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5f811bebef837ff0367d28aa777df5c8b43795cab6f9ff385cce49abb4e04a6f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5f811bebef837ff0367d28aa777df5c8b43795cab6f9ff385cce49abb4e04a6f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5f811bebef837ff0367d28aa777df5c8b43795cab6f9ff385cce49abb4e04a6f?s=96&d=mm&r=g\",\"caption\":\"Admin B.\"},\"url\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/author\\\/admin-b\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Triple Receptor Agonist Retatrutide Achieves Significant Reductions in HbA1c and Body Weight in Phase III Trial","description":"Retatrutide significantly improves hba1c and body weight outcomes, enhancing glycaemic control in adults with type 2 diabetes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.m3globalresearch.com\/blog\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\/","og_locale":"en_US","og_type":"article","og_title":"Triple Receptor Agonist Retatrutide Achieves Significant Reductions in HbA1c and Body Weight in Phase III Trial","og_description":"Stage 2 chronic kidney disease often goes unnoticed, with estimated glomerular filtration rate levels still within the kidney function threshold.","og_url":"https:\/\/www.m3globalresearch.com\/blog\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\/","og_site_name":"M3 Global Research","article_publisher":"https:\/\/en-gb.facebook.com\/M3GlobalResearch\/","article_published_time":"2026-06-15T13:07:42+00:00","article_modified_time":"2026-06-15T13:57:13+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/www.m3globalresearch.com\/blog\/wp-content\/uploads\/2026\/06\/HbA1c-and-Body-Weight-scaled.jpeg","type":"image\/jpeg"}],"author":"Admin B.","twitter_card":"summary_large_image","twitter_creator":"@M3GR_Community","twitter_site":"@M3GR_Community","twitter_misc":{"Written by":"Admin B.","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.m3globalresearch.com\/blog\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\/#article","isPartOf":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\/"},"author":{"name":"Admin B.","@id":"https:\/\/www.m3globalresearch.com\/blog\/#\/schema\/person\/2694d930280885a6f8adfd3c7090c10b"},"headline":"Triple Receptor Agonist Retatrutide Achieves Significant Reductions in HbA1c and Body Weight in Phase III Trial","datePublished":"2026-06-15T13:07:42+00:00","dateModified":"2026-06-15T13:57:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\/"},"wordCount":296,"commentCount":0,"publisher":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/#organization"},"image":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.m3globalresearch.com\/blog\/wp-content\/uploads\/2026\/06\/HbA1c-and-Body-Weight-scaled.jpeg","articleSection":["Latest Medical News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.m3globalresearch.com\/blog\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\/#respond"]}]},{"@type":["WebPage","MedicalWebPage"],"@id":"https:\/\/www.m3globalresearch.com\/blog\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\/","url":"https:\/\/www.m3globalresearch.com\/blog\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\/","name":"Triple Receptor Agonist Retatrutide Achieves Significant Reductions in HbA1c and Body Weight in Phase III Trial","isPartOf":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\/#primaryimage"},"image":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.m3globalresearch.com\/blog\/wp-content\/uploads\/2026\/06\/HbA1c-and-Body-Weight-scaled.jpeg","datePublished":"2026-06-15T13:07:42+00:00","dateModified":"2026-06-15T13:57:13+00:00","description":"Retatrutide significantly improves hba1c and body weight outcomes, enhancing glycaemic control in adults with type 2 diabetes.","breadcrumb":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.m3globalresearch.com\/blog\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.m3globalresearch.com\/blog\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\/#primaryimage","url":"https:\/\/www.m3globalresearch.com\/blog\/wp-content\/uploads\/2026\/06\/HbA1c-and-Body-Weight-scaled.jpeg","contentUrl":"https:\/\/www.m3globalresearch.com\/blog\/wp-content\/uploads\/2026\/06\/HbA1c-and-Body-Weight-scaled.jpeg","width":2560,"height":1707,"caption":"Retatrutide significantly improves hba1c and body weight outcomes, enhancing glycaemic control in adults with type 2 diabetes."},{"@type":"BreadcrumbList","@id":"https:\/\/www.m3globalresearch.com\/blog\/triple-receptor-agonist-retatrutide-achieves-significant-reductions-in-hba1c-and-body-weight-in-phase-iii-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.m3globalresearch.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Triple Receptor Agonist Retatrutide Achieves Significant Reductions in HbA1c and Body Weight in Phase III Trial"}]},{"@type":"WebSite","@id":"https:\/\/www.m3globalresearch.com\/blog\/#website","url":"https:\/\/www.m3globalresearch.com\/blog\/","name":"M3 Global Research","description":"","publisher":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.m3globalresearch.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.m3globalresearch.com\/blog\/#organization","name":"M3 Global Research","url":"https:\/\/www.m3globalresearch.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.m3globalresearch.com\/blog\/#\/schema\/logo\/image\/","url":null,"contentUrl":null,"width":null,"height":null,"caption":"M3 Global Research"},"image":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/en-gb.facebook.com\/M3GlobalResearch\/","https:\/\/x.com\/M3GR_Community","https:\/\/www.instagram.com\/m3globalresearch","https:\/\/www.linkedin.com\/company\/10557915"]},{"@type":"Person","@id":"https:\/\/www.m3globalresearch.com\/blog\/#\/schema\/person\/2694d930280885a6f8adfd3c7090c10b","name":"Admin B.","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/5f811bebef837ff0367d28aa777df5c8b43795cab6f9ff385cce49abb4e04a6f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/5f811bebef837ff0367d28aa777df5c8b43795cab6f9ff385cce49abb4e04a6f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5f811bebef837ff0367d28aa777df5c8b43795cab6f9ff385cce49abb4e04a6f?s=96&d=mm&r=g","caption":"Admin B."},"url":"https:\/\/www.m3globalresearch.com\/blog\/author\/admin-b\/"}]}},"jetpack_featured_media_url":"https:\/\/www.m3globalresearch.com\/blog\/wp-content\/uploads\/2026\/06\/HbA1c-and-Body-Weight-scaled.jpeg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/posts\/171185","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/comments?post=171185"}],"version-history":[{"count":18,"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/posts\/171185\/revisions"}],"predecessor-version":[{"id":171272,"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/posts\/171185\/revisions\/171272"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/media\/171234"}],"wp:attachment":[{"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/media?parent=171185"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/categories?post=171185"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/tags?post=171185"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}